Where does Avantec Vascular Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Avantec Vascular Corporation ranks #13,875 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Avantec Vascular Corporation hold?

Avantec Vascular Corporation holds 21 US utility patents granted between 2018 and 2025, spanning 4 technology areas.

What is Avantec Vascular Corporation's Innovation Score?

Avantec Vascular Corporation has an Innovation Score of 34.5 out of 100 (48th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Avantec Vascular Corporation focus on?

Avantec Vascular Corporation's top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 17 patents, ranking #1,046 of 7,127 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Avantec Vascular Corporation's patent grant rate increasing or decreasing?

Avantec Vascular Corporation's recent grant velocity is +225% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Avantec Vascular Corporation's patents?

Avantec Vascular Corporation's patents average 15.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Avantec Vascular Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Avantec Vascular Corporation

USPTO PatentsView assignee record - 21 granted patents across 4 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Avantec ranks #13,875 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 4 technology areas.

#13,875
of 49,997 US assignees by volume: 48th percentile
by Innovation Score (34.5/100): 15.1
avg claims per patent: +225%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13875 · US Corporation #13,875 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 21 grants
MID-PACK #13,875/49,997
PHOTO-FINISH Acerta Pharma B V
CPC-NARROW A61B · 4 areas
INNOV-THIN 34.5/100
CLAIMS-RICH 15.1 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +225% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Acerta Pharma B.V. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Avantec’s 34.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (31%) Velocity 7.6 pts (22%) Breadth 7.1 pts (21%) Claim depth 9.1 pts (26%)

Qualcomm Incorporated · highest

85
Avantec Vascular · this assignee

34
3D Lighting… · lowest

7

What this shows Avantec's Innovation Score is 34.5/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Avantec?

Each dot is one of Avantec’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Avantec’s own 15.1 claims/patent is ABOVE the 13.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Avantec vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Avantec's grants concentrate

Avantec Vascular Corporation is a focused PatentsView assignee: 4 CPC subclasses with 81% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2021 (3 grants) versus a trough of 2 in 2018. By volume, Avantec sits between Artika FOR Living Inc. and Adherium (NZ) Limited.

Avantec's three-year grant acceleration

Avantec Vascular Corporation shows 8 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Artika FOR Living

21
Ascentage Pharma…

21
Asterias Biothera…

21
Atlas Copco Airpo…

21
Acerta Pharma B V

21
Active Implants

21
Adasky

21
Adherium (NZ)

21
Avantec Vascular ◀

21

What this shows Avantec holds 21 patents at rank #13,850, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Avantec

By rank, the assignees closest to #13,850 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Avantec's primary technology class.

Avantec's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 48th percentile higher than 48% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Avantec Vascular Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	2	9.5%
2019	2	9.5%
2020	2	9.5%
2021	3	14.3%
2022	3	14.3%
2023	2	9.5%
2024	3	14.3%
2025partial year	4	19.0%

Which technologies does Avantec Vascular Corporation patent most?

A61B - DIAGNOSIS; SURGERY; Identification 17

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 13

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 8

B21F - Working OR Processing OF Metal Wire 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Avantec Vascular Corporation's patent record in context - here's where to go next.

Avantec Vascular Corporation's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 81% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #13,875 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Avantec Vascular Corporation against Artika FOR Living Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.